[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349049-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349049-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-emerging-role-of-tertiary-lymphoid-structures-as-predictive-and-prognostic-biomarkers-of-immunotherapy-in-cancer","The Emerging Role of Tertiary Lymphoid Structures as Predictive and Prognostic Biomarkers of Immunotherapy in Cancer","","Immune checkpoint inhibitors improve outcomes across several cancers, yet many patients remain non-responsive, driving the need for reliable predictive biomarkers. This review examines tertiary lymphoid structures (TLS) as ectopic immune aggregates that support local antigen presentation and adaptive immune activation. It synthesizes clinical and translational evidence in solid malignancies, linking TLS presence, organisation, and function with survival and immunotherapy response. Results highlight favourable immune activity, while emphasizing assessment variability and the need for standardization.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-emerging-role-of-tertiary-lymphoid-structures-as-predictive-and-prognostic-biomarkers-of-immunotherapy-in-cancer/349049/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-emerging-role-of-tertiary-lymphoid-structures-as-predictive-and-prognostic-biomarkers-of-immunotherapy-in-cancer/349049.png","ImageObject",300,407,{"name":42,"@type":43},"Sarah ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are predictive biomarkers needed for cancer immunotherapy?","Question",{"text":63,"@type":64},"Many patients do not respond to immune checkpoint inhibitors, despite improved outcomes overall. This creates a need for robust markers that can forecast response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are tertiary lymphoid structures (TLS) and where do they occur?",{"text":68,"@type":64},"TLS are ectopic immune aggregates formed in non-lymphoid tissues under chronic inflammation, including within the tumour microenvironment. They can appear inside tumours or in the peritumoural region.",{"name":70,"@type":61,"acceptedAnswer":71},"How do TLS relate to prognosis and immunotherapy response?",{"text":72,"@type":64},"Across multiple tumour types, TLS correlate with improved survival and enhanced anti-tumour immune activity. TLS maturity, especially germinal-centre-like features, is reported to strengthen predictive value for immune checkpoint inhibitor benefit.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349049,1790385137,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Medicine  \nREVIEW  OPEN ACCESS   \nThe Emerging Role of Tertiary Lymphoid Structures as Predictive and Prognostic Biomarkers of Immunotherapy in Cancer  \nLidia B. Medhin1,2  | Rodas Amanuel3,4 | Lydia Warburton1,2,5 | Leslie Calapre1,2 | Benhur Amanuel1,2 | Elin S. Gray1,2   \n1Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia | 2School of Medical and Health Sciences, Edith  \nCowan University, Joondalup, Western Australia, Australia | 3School of Medicine, University of Western Australia, Crawley, Western Australia, Australia | 4Faculty of Health Science and Medicine, Bond University, Robina, Queensland, Australia | 5Department of Medical Oncology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia  \nCorrespondence: Elin S. Gray ([e.gray@ecu.edu.au](e.gray@ecu.edu.au))  \nReceived: 11 August 2025 | Revised: 15 February 2026 | Accepted: 2 March 2026  \nKeywords: biomarker | immunotherapy | tertiary lymphoid structures  \nABSTRACT  \nBackground: Immune checkpoint inhibitors (ICIs) have improved outcomes across several cancers, yet many patients do not respond, highlighting the need for robust predictive biomarkers. Tertiary lymphoid structures (TLS), ectopic lymphoid aggre‑ gates that support local antigen presentation and adaptive immune activation, have emerged as potential indicators of favourable prognosis and immunotherapy responsiveness.  \nMethods: This review summarises current clinical and translational evidence examining the prognostic and predictive value of TLS in solid malignancies. Studies assessing TLS presence, organisation, and biological function were identified through searches of major scientific databases and evaluated with respect to their association with patient outcomes and responses to ICIs.  \nResults: Across multiple tumour types, TLS correlate with improved survival and enhanced anti‑tumour immune activity. TLS‑rich tumours typically show increased infiltration of effector immune cells and more inflamed tumour microenvironments. Several studies also indicate that TLS maturity, particularly the presence of germinal‑centre‑like features, strengthens their predictive value for ICI benefit. However, substantial variation exists in TLS assessment methods and definitions, limiting com‑ parability and hindering translation into routine clinical use.  \nConclusions: TLS represent a promising biomarker for prognosis and immunotherapy response. Standardised evaluation meth‑ ods and prospective clinical validation are essential to enable their integration into personalised treatment strategies.  \n1 | Introduction  \nTertiary Lymphoid Structures (TLS) are ectopic, immune aggre‑ gates that form in non‑lymphoid tissues in response to chronic inflammation, including within the tumour microenvironment (TME) [1] . They can be found either within tumours or in the peritumoural region [2] . The term ‘tertiary’ was first used in 1992 by Picker and Butcher to describe lymphoid structures in  \nperipheral tissues [3], and later proposed by Takemura et [al. in](al. in)[ ](al. in)2001, in their work on germinal centres in rheumatoid synovitis [4](Figure 2) .  \nIncreasing evidence indicates that TLS influence antitumour immunity, particularly in the context of cancer immunother‑ apy [5] . As a result, TLS have gained attention as a potential prognostic and predictive biomarker. However, their clinical  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71728 1 of 8  \n[https://doi.org/10.1002/cam4.71728](https://doi.org/10.1002/cam4.71728)  \nFIGURE 1 | Developmental stages of TLS. Early TLS are marked by CD20+ B‑cell clusters and CD3+ CD4+ T‑cells, while primary TLS show more organisation with CD21+ immature follicular dendri","cbCaivqx2DH3Hpk6","https://ap.wps.com/l/cbCaivqx2DH3Hpk6","pdf",2301786,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Structural Organisation of TLS","[{\"question\":\"Why are predictive biomarkers needed for cancer immunotherapy?\",\"answer\":\"Many patients do not respond to immune checkpoint inhibitors, despite improved outcomes overall. This creates a need for robust markers that can forecast response.\"},{\"question\":\"What are tertiary lymphoid structures (TLS) and where do they occur?\",\"answer\":\"TLS are ectopic immune aggregates formed in non-lymphoid tissues under chronic inflammation, including within the tumour microenvironment. They can appear inside tumours or in the peritumoural region.\"},{\"question\":\"How do TLS relate to prognosis and immunotherapy response?\",\"answer\":\"Across multiple tumour types, TLS correlate with improved survival and enhanced anti-tumour immune activity. TLS maturity, especially germinal-centre-like features, is reported to strengthen predictive value for immune checkpoint inhibitor benefit.\"}]","The Emerging Role of Tertiary Lymphoid Structures as Predictive and Prognostic Biomarkers of Immunotherapy in Cancer | PDF",1790081366,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/780c3c16935161c12059be98b7cd5610.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04e189d54b24f9ac9bbeaa8a1cefa006.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68c899780b07c054cab745bd4666c82f.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9791f6bdef7b39301dac78cba7ea497f.webp",980,1287]